A detailed history of Brown Brothers Harriman & CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 1,346 shares of GILD stock, worth $118,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,346
Previous 1,710 21.29%
Holding current value
$118,555
Previous $125,000 26.4%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$63.15 - $72.88 $22,986 - $26,528
-364 Reduced 21.29%
1,346 $92,000
Q1 2024

May 10, 2024

BUY
$71.58 - $87.29 $51,537 - $62,848
720 Added 72.73%
1,710 $125,000
Q4 2023

Feb 12, 2024

SELL
$73.27 - $83.09 $12,602 - $14,291
-172 Reduced 14.8%
990 $80,000
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $41,997 - $45,820
568 Added 95.62%
1,162 $87,000
Q2 2023

Aug 07, 2023

SELL
$76.01 - $86.7 $1,824 - $2,080
-24 Reduced 3.88%
594 $45,000
Q1 2023

May 11, 2023

SELL
$77.31 - $88.08 $9,818 - $11,186
-127 Reduced 17.05%
618 $51,000
Q4 2022

Feb 09, 2023

SELL
$62.32 - $89.47 $51,414 - $73,812
-825 Reduced 52.55%
745 $63,000
Q3 2022

Nov 10, 2022

SELL
$59.54 - $68.01 $11,908 - $13,602
-200 Reduced 11.3%
1,570 $97,000
Q2 2022

Aug 11, 2022

BUY
$57.72 - $65.01 $11,255 - $12,676
195 Added 12.38%
1,770 $109,000
Q1 2022

May 13, 2022

SELL
$57.92 - $72.58 $36,547 - $45,797
-631 Reduced 28.6%
1,575 $94,000
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $1,232 - $1,399
19 Added 0.87%
2,206 $160,000
Q3 2021

Nov 15, 2021

SELL
$67.69 - $73.03 $53,407 - $57,620
-789 Reduced 26.51%
2,187 $153,000
Q2 2021

Aug 13, 2021

SELL
$63.47 - $69.35 $29,323 - $32,039
-462 Reduced 13.44%
2,976 $205,000
Q1 2021

May 13, 2021

SELL
$60.0 - $68.46 $217,080 - $247,688
-3,618 Reduced 51.28%
3,438 $222,000
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $9,120 - $10,392
161 Added 2.34%
7,056 $411,000
Q3 2020

Nov 16, 2020

SELL
$62.1 - $78.08 $66,198 - $83,233
-1,066 Reduced 13.39%
6,895 $436,000
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $84,782 - $98,448
1,172 Added 17.26%
7,961 $613,000
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $241,689 - $309,568
-3,859 Reduced 36.24%
6,789 $508,000
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $114,120 - $125,528
-1,852 Reduced 14.82%
10,648 $692,000
Q3 2019

Nov 14, 2019

BUY
$62.51 - $69.0 $200,407 - $221,214
3,206 Added 34.5%
12,500 $792,000
Q2 2019

Aug 14, 2019

SELL
$61.87 - $69.38 $70,469 - $79,023
-1,139 Reduced 10.92%
9,294 $628,000
Q1 2019

May 15, 2019

BUY
$62.53 - $70.05 $480,292 - $538,054
7,681 Added 279.11%
10,433 $678,000
Q4 2018

Feb 14, 2019

SELL
$60.54 - $79.0 $784,719 - $1.02 Million
-12,962 Reduced 82.49%
2,752 $172,000
Q3 2018

Nov 14, 2018

SELL
$71.28 - $78.92 $85,464 - $94,625
-1,199 Reduced 7.09%
15,714 $1.21 Million
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $88,366 - $103,076
1,362 Added 8.76%
16,913 $1.2 Million
Q1 2018

May 14, 2018

BUY
$72.84 - $88.8 $979,916 - $1.19 Million
13,453 Added 641.23%
15,551 $1.17 Million
Q4 2017

Feb 14, 2018

BUY
$71.15 - $83.52 $127,358 - $149,500
1,790 Added 581.17%
2,098 $150,000
Q3 2017

Nov 14, 2017

SELL
$72.11 - $85.47 $18,388 - $21,794
-255 Reduced 45.29%
308 $25,000
Q2 2017

Aug 14, 2017

BUY
N/A
563
563 $40,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.